Related Experiment Video
Updated: Feb 18, 2026
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Potential Anticancer Mechanisms of a Novel EGFR/DNA-Targeting Combi-Molecule (JDF12) against DU145 Prostate Cancer
Haofeng Zheng1, Guancan Liang1, Yanxiong Chen1
1Department of Urology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.
Abstract:
The development of multitargeting drugs is an emerging trend in cancer research. To promote further development and clinical application of multitargeting drugs, this research was performed. MTT assay and flow cytometry of Annexin V/propidium iodide staining were used to confirm the proapoptotic efficacy of a novel combi-targeting molecule, JDF12, against DU145 prostate cancer (PCa) cells. Differentially expressed proteins between control and JDF12-treated cultures were revealed by isobaric tags for relative and absolute quantitation (iTRAQ), and part of them was confirmed by quantitative PCR. Differentially expressed proteins were further analyzed for function, pathway association, and protein-protein interactions using GO, KEGG, and STRING databases. A total of 119 differentially expressed proteins, 70 upregulated and 49 downregulated, were implicated in the anticancer effects of JDF12. Many of these proteins are involved in biosynthesis, response to stress, energy metabolism, and signal transduction. This study provides important information for understanding the anti-PCa mechanisms of JDF12, and well-designed combi-targeting drugs may possess stronger anticancer efficacy than single-targeting drugs and are thus promising candidates for clinical application.
Insights
A novel combi-targeting molecule, JDF12, shows proapoptotic effects against prostate cancer cells. This study identifies 119 differentially expressed proteins involved in JDF12's anticancer mechanisms, highlighting potential for new drug development.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Multitargeting drugs represent a growing area in cancer research.
- Understanding novel therapeutic agents is crucial for advancing cancer treatment.
Purpose of the Study:
- To investigate the anti-prostate cancer (PCa) efficacy of a novel combi-targeting molecule, JDF12.
- To elucidate the molecular mechanisms underlying JDF12's action in PCa cells.
Main Methods:
- MTT assay and Annexin V/propidium iodide staining for apoptosis assessment.
- Isobaric tags for relative and absolute quantitation (iTRAQ) for proteomic analysis.
- Quantitative PCR, Gene Ontology (GO), KEGG, and STRING databases for data validation and pathway analysis.
Main Results:
- JDF12 demonstrated significant proapoptotic effects on DU145 PCa cells.
- A total of 119 differentially expressed proteins (70 upregulated, 49 downregulated) were identified.
- Key proteins involved in biosynthesis, stress response, energy metabolism, and signal transduction were implicated.
Conclusions:
- JDF12 exhibits potent anticancer effects against prostate cancer through modulation of multiple cellular pathways.
- Combi-targeting drugs offer enhanced efficacy compared to single-targeting agents.
- These findings support the clinical potential of JDF12 and similar multitargeting drugs for prostate cancer therapy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:38Mitogens and the Cell Cycle